Amy Wang

Dyno Therapeutics, Inc. engages in the development of therapeutics technologies. It develops technologies for safe, efficient and targeted in vivo delivery of new gene therapies and genome editing therapies. The company was founded by Kelsic Eric David and is headquartered in Watertown, MA.

Remiges Ventures Inc. (Remiges Ventures) is a venture capital firm founded in 2014 by Taro Inaba. It is headquartered in Cambridge, United States.

Superluminal Medicines Inc is a generative biological and chemical company. The company is based in Boston, MA. The CEO of the company is Cony D'Cruz.

ImmuneBridge, Inc. is a biotech company that is developing the next generation of allogeneic cellular medicines to make curative cancer therapies accessible to everyone. The company is based in San Francisco, CA and was founded in 2018 by Jesse Cotari and Peretz Partensky. The company is starting with NK cell-based immunotherapies. The company's proprietary expansion technology amplifies cord blood-derived immune stem cells while maintaining full immune multipotency to create a consistent and abundant cellular source for immunotherapies. ImmuneBridge's scientific approach harnesses this expansion technology along with the unique benefits of umbilical cord blood to enable robust screening and selection for the most potent cancer-fighting cells. Peretz Partensky has been the CEO since 2018.

Gameto, Inc. is a biotechnology company based in New York, NY that focuses on developing novel treatment solutions for women's health, starting with infertility. The company's lead program, Fertilo, aims to make IVF and egg freezing shorter, safer, and more accessible through reduced hormonal injections by maturing eggs outside of the body. The company's goal is to improve assisted fertility outcomes, make the medical burden of menopause optional, and redefine female reproductive health by testing and developing drugs for ovarian disease. Gameto is led by CEO Dina Radenkovic, a physician-turned-entrepreneur, and Chairman Martin Varsavsky, a serial entrepreneur and founder of the largest fertility network, Prelude Fertility.

DEM BioPharma, Inc. is an American company that pioneers the next generation of immunotherapeutics to eliminate tumors by targeting 'don't eat me' and 'eat me' signals on cancer cells, macrophages, and other myeloid effector cells. The company is based in Cambridge, MA. The proprietary CHOMP™ platform utilizes CRISPR-based functional genomic screens to discover and validate new signals that could enhance cancer cell elimination through increased phagocytosis. The company was founded by Longwood Fund and builds on groundbreaking functional genomics research and discoveries in macrophage biology from its scientific co-founders. Nenad Grmusa has been the CEO of the company since 2022.

Switch Therapeutics, Inc. is an American biotechnology company that aims to treat a range of diseases affecting the central nervous system and systemic indications with significant unmet need. Switch is based in , and was founded by Dee Datta, who has been the CEO since incorporation. The company is pioneering a new type of medicine that integrates nucleic acid nanotechnology and RNA interference (RNAi) science. The company's novel gene knockdown approach, the Conditionally Activated siRNA (CASI) platform, is based on technology developed by renowned researchers in the field of RNA and drug development from Caltech, Harvard Medical School, and City of Hope.

Charles River Ventures, Inc. is a venture capital firm founded in 1970. The firm is headquartered in Cambridge, Massachusetts.

Integrated Plasmonics Corp. operates as a nanotechnology company. The company was founded on February 4, 2011 and is headquartered in San Francisco, CA.

Insight Venture Management LLC (Insight Venture Partners) is a private equity/ venture capital subsidiary of Insight Holdings Group LLC founded in 1995 by Jeffrey L. Horing and Jerry Fred Murdock. The firm is headquartered in New York.

Vecprobio Inc. develops manufacturing technologies and tools for gene therapy. The company is based in San Diego, CA. The company was founded in 2022. Daniel Gibbs has been the CEO of the company since 2022.

ArrePath, Inc. is an anti-infective drug discovery company that focuses on addressing the health challenge of drug-resistant infections. The platform's proof-of-concept has been demonstrated in studies published in Cell by ArrePath's scientific founder, Zemer Gitai, Ph.D., Edwin Grant Conklin Professor of Biology at Princeton University. The company is based in Princeton, NJ, and is funded by the Boehringer Ingelheim Venture Fund, Insight Partners, Innospark Ventures, Viva BioInnovator, Arimed Capital, PTX Capital, and Nor'easter Ventures. The company utilizes a proprietary machine learning-based platform to efficiently identify anti-infective agents with new mechanisms of action at the outset of the discovery process. This is achieved through a deep understanding and analysis of pathogen behavior. The CEO of the company is Lloyd J. Payne.

Unlearn.AI, Inc. develops machine learning technology for clinical drug trails. It offers clinical trial design, synthetic control arms, and super-powered subgroup analysis. The company was founded by Aaron Smith, Charles K. Fisher, and Jonathan Walsh in 2017 and is headquartered in San Francisco, CA.

Deciduous Therapeutics, Inc. engages in the biotechnology business. It develops novel therapies to activate the endogenous immune system to treat age related diseases. The company is headquartered in San Francisco, CA.

G.I. View Ltd. develops endoscopy products for gastrointestinal applications. It offers edge endoscopes for the gastrointestinal market that set its products. The company was founded by Benad Goldwasser, Oz Cabiri and Yossi Gross in 2003 and is headquartered in Ramat Gan, Israel.

Shoni Health Ventures (Shoni Health Ventures) is a venture capital firm founded in 2021 by Sara Greenberg and Ran Goshen. The firm is headquartered in Ramat Gan, Israel.

Innoventric Ltd. engages in the development of technologies for the treatment of cardiovascular diseases. The company was founded by Amir Danino on February 15, 2016 and is headquartered in Ness Ziona, Israel.

Medial Earlysign Ltd. develops an AI algorithmic platform for the discovery of clinical insights that indicate the likelihood of disease from basic medical information, such as blood test results, and other EMR data. The company was founded by Ofer Ariely, Nir Kalkstein and Ori Geva in 2009 and is headquartered in Kfar Malal, Israel.

Dbmotion Ltd. provides healthcare information integration software solutions. It develops and markets the dbMotion Solution, a proven SOA-based platform that enables healthcare organizations and exchanges to meaningfully integrate and leverage their information assets, driving improvements in the quality, safety and efficiency of patient care. It was founded in 2004 by Yuval Ofek, Assaf Halevy and Ziv Ofek and is headquartered in Be'er Sheva, Israel.

Tautona Group (Tautona Group) is a venture capital firm founded in 2010 by Duke Rohlen. The firm is headquartered in Menlo Park, California.

Symic Bio, Inc. develops new category of therapeutics. The company studies treatments for osteoarthritis and cardiovascular ailments. The firm developed a new therapeutic category of bioconjugates that directly target the extracellular matrix, the biologically active environment which plays critical roles for cell proliferation, migration, differentiation and survival. The company was founded by Kate Stuart and John Paderi in 2012 and is headquartered in San Francisco, CA.

Bay Area Discovery Museum operates as a preschool. The private company is based in Sausalito, CA and has subsidiaries in the United States.

Symic Holdings LLC develops new category of therapeutics. The company was founded by John Paderi, Kate Stuart and Alyssa Panitch and is headquartered in Emeryville, CA.

Teon Therapeutics, Inc. operates as a pharmaceutical company. It focuses on cancer immunotherapy. The company was founded by Yao Lina, Fan Peidong, Elfaith Elzein, and Liiu Jiwen in March 2018 and is headquartered in Redwood City, CA.

Digestome Therapeutics, Inc. is a company that focuses on developing sar-optimized drug candidates for various conditions such as depression, anxiety, inflammatory disease, and tinnitus. The company is based in San Francisco, CA. The company's drug candidates are gut-acting and gut-restricted, which provides a safer profile compared to most approved psychiatric drugs. The company was founded in 2018 by Kousaku Ohinata, and the CEO is Kenneth Nicholas Horne.